MetaCap

Autolus Therapeutics (AUTL) vs Cabaletta Bio (CABA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics (AUTL) has outperformed Cabaletta Bio (CABA) over the past year, losing 26.2% versus a loss of 55.0%. Over five years, AUTL leads with a -85.5% price change compared with -91.9% for CABA. Autolus Therapeutics is the larger company by market cap ($241.7 million vs $201.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-26.24%CABA-55.00%
+115%+26%-63%
Nov 21, 20251 yearNov 20, 2026
AUTL-85.41%CABA-92.19%
+119%+7%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus CABA key metrics
MetricAUTLCABA
Share price$0.9073$0.9361
Market cap$241.65M$201.94M
1-day change-7.38%-7.32%
YTD return-54.41%-57.26%
1-year return-26.24%-55.00%
5-year return-85.51%-91.93%
EPS (TTM)$-0.96$-1.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M—
Revenue growth (YoY)+644.94%—
Net income (latest FY)$-287.53M$-167.86M
Gross margin-27.83%—
Operating margin-358.87%—
Net margin-381.40%—
52-week high$2.58$4.23
52-week low$0.896$0.93
Distance from 52-week high-64.83%-77.87%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+821.42%+1155.21%
Average volume2.07M5.15M
Shares outstanding266.34M215.72M
Employees752154
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AUTL has outperformed CABA by 28.8 percentage points over the past year.

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

AUTL vs CABA FAQ

Which is bigger, Autolus Therapeutics or Cabaletta Bio?

Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $201.94M for Cabaletta Bio (CABA).

Which stock has performed better over the past year, AUTL or CABA?

AUTL returned -26.24% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.

Are Autolus Therapeutics and Cabaletta Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons